Alzprotect, of Lille, France, engaged in the development of drugs for the treatment of Alzheimer's disease (AD), said that Parexel Biotech, a new division of Parexel International Corp., of Waltham, Mass., will perform the clinical phase IIa development of AZP-2006 for the treatment of progressive supranuclear palsy, a rare degenerative disease of the brain.